| Waleska Pillich Ortiz, CRNA | |
|
Calle 2 Aa#20 Almira, Levittown, PR 00949-4007 | |
| (787) 923-1023 | |
| Not Available |
| Full Name | Waleska Pillich Ortiz |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | Calle 2 Aa#20 Almira, Levittown, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346569696 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 9309002 (Florida) | Primary |
| 367500000X | Nurse Anesthetist, Certified Registered | 1539 (Puerto Rico) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Waleska Pillich Ortiz, CRNA 2346 Bellarosa Cir, Royal Palm Beach, FL 33411-1468 Ph: (551) 291-2703 | Waleska Pillich Ortiz, CRNA Calle 2 Aa#20 Almira, Levittown, PR 00949-4007 Ph: (787) 923-1023 |
News Archive
"Many interesting research questions now lie ahead. But most urgent will be the assessment of the practical impact of these findings and their public health importance in generalised epidemics," according to a Lancet editorial about last week's release of study results showing early HIV treatment dramatically reduces transmission risk.
An Accenture-led consortium has won the pivotal contract to deliver a national IT infrastructure for the Gillard government's $500 million personally controlled e-health records system. The team including Oracle and Orion Health also won $146m contract to deliver Singapore's e-health records program last year.
A protein long known to be involved in protecting a cell from genetic damage has been found to play an even more important role in protecting the cell's offspring.
Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA's Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.
› Verified 2 days ago